Zobrazeno 1 - 10
of 440
pro vyhledávání: '"D, Sainty"'
Autor:
J. Rey, Rodolphe Jean, D. Figarella-Branger, E. Crétel-Durand, J.M. Durand, D. Sainty, M.-O. Chandesris
Publikováno v:
La Revue de Médecine Interne. 28:552-555
Resume Introduction Les lymphomes malins non hodgkiniens exprimant le recepteur T gamma delta pour l'antigene (GDTL) sont un groupe rare et heterogene de lymphomes atteignant principalement la rate et le foie et plus rarement la peau, l'intestin ou l
Autor:
R. Bouabdallah, Patrick Ladaique, Didier Blaise, Karin Bilger, Mohamad Mohty, Norbert Vey, Christian Chabannon, D. Sainty, J. Camerlo, C. Arnoulet, Vadim Ivanov, D. Maraninchi, Catherine Faucher, V.J. Bardou
Publikováno v:
Transfusion. 44:501-508
BACKGROUND: RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type. STUDY DESIGN AND METHODS: An analysis was done of RBCT requirements and Hb recovery kinetic in the first 60 day
Autor:
R. Naumann, R. Nowak, D. Sainty, I. Besson, C. Arnoulet, G. Ehninger, Y. Bux, U. Oelschlaegel
Publikováno v:
Clinical & Laboratory Haematology. 23:81-90
PNH is a disorder of the pluripotent stem cells resulting in a deficient expression of membrane-bound GPI-anchored proteins in different cell types. Several flow cytometric approaches are designed to detect this antigen deficiency. But they all requi
Autor:
P. Validire, D. Sainty, L. Edelman, C. Arnoulet, E. Monchâtre, J.-C. Durand, J.P. Lotz, C Bayle
Publikováno v:
Hematology and Cell Therapy. 41:66-70
Through two clinical studies, tumor cells were searched for in the bone biopsies and cytapherisis of patients suffering from inflammatory tumors and who had undergone intensive therapy and autografts (Pegase 2 program). In these studies we used immun
Autor:
D. Sainty, Didier Blaise, R. Bouabdallah, Luc Xerri, Dominique Maraninchi, V.J. Bardou, Stoppa Am, J. A. Gastaut
Publikováno v:
Annals of Oncology. 9:619-625
Summary Objective To describe the outcome of an unselected large series of patients with lymphoblastic lymphoma (LBL) treated in a single institution. Patients and methods Sixty-two patients were treated between 1980 and 1992. Induction chemotherapy
Publikováno v:
La Revue de Médecine Interne. 17:213-223
Resume La leucemie myeloide chronique (LMC) est une proliferation clonale d'une cellule immature qui touche les lignees my eloide, erythroide, megacaryocytaire, lymphoide B et les cellules natural killer (NK). Le caryotype met en evidence de facon pr
Autor:
J. Serratrice, Nicoleta Ene, Norbert Vey, B. Granel, D. Sainty, Patrick Disdier, Pierre-Jean Weiller
Publikováno v:
La Revue de Médecine Interne. 25:770-772
Autor:
C, Gervais, A, Murati, C, Helias, S, Struski, A, Eischen, E, Lippert, I, Tigaud, D, Penther, C, Bastard, F, Mugneret, B, Poppe, F, Speleman, P, Talmant, J, VanDen Akker, L, Baranger, C, Barin, I, Luquet, N, Nadal, F, Nguyen-Khac, O, Maarek, C, Herens, D, Sainty, G, Flandrin, D, Birnbaum, M-J, Mozziconacci, M, Lessard, Catherine, Settegrana
Publikováno v:
Leukemia. 22(8)
Thirty cases of acute myeloid leukaemia (AML) with MYST histone acetyltransferase 3 (MYST3) rearrangement were collected in a retrospective study from 14 centres in France and Belgium. The mean age at diagnosis was 59.4 years and 67% of the patients
Autor:
M-O, Chandesris, E, Crétel-Durand, R, Jean, J, Rey, D, Figarella-Branger, D, Sainty, J-M, Durand
Publikováno v:
La Revue de medecine interne. 28(8)
Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid malignancies, accounting for approximately 10-15% of all non-Hodgkin's lymphomas. A rare entity within this group is represented by hepatosplenic T cell lymphoma, c
Autor:
V, Ivanov, C, Faucher, M, Mohty, K, Bilger, P, Ladaique, D, Sainty, C, Arnoulet, C, Chabannon, N, Vey, J, Camerlo, R, Bouabdallah, D, Maraninchi, V J, Bardou, D, Blaise
Publikováno v:
Transfusion. 44(4)
RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type.An analysis was done of RBCT requirements and Hb recovery kinetic in the first 60 days after HLA-identical sibling allogenei